KEYNOTE-522 Study of Pembro plus Chemo vs. Placebo plus Chemo as Neoadjuvant Treatment Followed by Pembro vs. Placebo as Adjuvant Treatment for Early TNBC: Pathologic Complete Response in Key Subgroups

被引：0
|
作者：
Schmid, P. [1 ]
机构：
[1] Barts Canc Inst, Ctr Expt Med, London, England
来源：
ANNALS OF SURGICAL ONCOLOGY | 2020年 / 27卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P38
引用
收藏
页码：S129 / S129
页数：1
相关论文
共 50 条
  • [21] Phase III study of neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for early-stage triple-negative breast cancer (TNBC): KEYNOTE-522 Korean subgroup analysis
    Park, Y. H.
    Im, S-A.
    Ahn, J-H.
    Kim, M. H.
    Cortes, J.
    Dent, R. A.
    Pusztai, L.
    McArthur, H. L.
    Kummel, S.
    Denkert, C.
    O'Shaughnessy, J.
    Mouret-Reynier, M-A.
    Ferreira, M. I. R.
    Cortes, M. Gion
    Boileau, J-F.
    Hui, R.
    Zhu, Y.
    Pan, W.
    Karantza, V. V.
    Schmid, P.
    ANNALS OF ONCOLOGY, 2023, 34 : S1467 - S1468
  • [22] Pembrolizumab or placebo plus chemotherapy followed by pembrolizumab or placebo for early-stage TNBC: Updated EFS results from the phase III KEYNOTE-522 study
    Schmid, P.
    Cortes, J.
    Dent, R. A.
    Pusztai, L.
    McArthur, H. L.
    Kummel, S.
    Denkert, C.
    Park, Y. H.
    Hui, R.
    Harbeck, N.
    Takahashi, M.
    Foukakis, T.
    Reynier, M. A. Mouret
    Ferreira, M. I. R.
    Im, S. A.
    Cardoso, F.
    Ding, Y.
    Pan, W.
    Tryfonidis, K. E.
    O'Shaughnessy, J.
    ANNALS OF ONCOLOGY, 2023, 34 : S1257 - S1257
  • [23] Health-related quality of life (HRQoL) with pembrolizumab (pembro) plus chemotherapy (chemo) vs placebo (pbo) + chemo as 1L treatment for advanced triple-negative breast cancer (TNBC): Results from KEYNOTE-355
    Cescon, D. W.
    Schmid, P.
    Rugo, H. S.
    Im, S-A.
    Yusof, M. Md
    Gallardo, C. E.
    Lipatov, O.
    Barrios, C. H.
    Perez Garcia, J. M.
    Iwata, H.
    Masuda, N.
    Torregroza Otero, M. A.
    Gokmen, E.
    Loi, S.
    Haiderali, A.
    Zhou, X.
    Guo, Z.
    Nguyen, A. Martin
    Cortes, J.
    ANNALS OF ONCOLOGY, 2022, 33 : S197 - S198
  • [24] KEYNOTE-756: Phase III study of neoadjuvant pembrolizumab (pembro) or placebo (pbo) plus chemotherapy (chemo), followed by adjuvant pembro or pbo plus endocrine therapy (ET) for early-stage high-risk ER+/HER2e breast cancer
    Cardoso, F.
    McArthur, H. L.
    Schmid, P.
    Cortes, J.
    Harbeck, N.
    Telli, M. L.
    Cescon, D. W.
    O'Shaughnessy, J.
    Fasching, P.
    Shao, Z.
    Loirat, D.
    Park, Y. H.
    Fernandez, M. E. Gonzalez
    Liu, Z.
    Yasojima, H.
    Ding, Y.
    Jia, L.
    Karantza, V. V.
    Tryfonidis, K. E.
    Bardia, A.
    ANNALS OF ONCOLOGY, 2023, 34 : S1260 - S1261
  • [25] KEYNOTE-189: Updated OS and progression after the next line of therapy (PFS2) with pembrolizumab (pembro) plus chemo with pemetrexed and platinum vs placebo plus chemo for metastatic nonsquamous NSCLC.
    Gadgeel, Shirish M.
    Garassino, Marina Chiara
    Esteban, Emilio
    Speranza, Giovanna
    Felip, Enriqueta
    Hochmair, Maximilian J.
    Powell, Steven Francis
    Cheng, Susanna Y.
    Bischoff, Helge
    Peled, Nir
    Hui, Rina
    Reck, Martin
    Kurata, Takayasu
    Garon, Edward B.
    Boyer, Michael J.
    Yang, Jing
    Pietanza, Maria Catherine
    Rodriguez-Abreu, Delvys
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [26] CheckMate 77T: Phase III study comparing neoadjuvant nivolumab (NIVO) plus chemotherapy (chemo) vs neoadjuvant placebo plus chemo followed by surgery and adjuvant NIVO or placebo for previously untreated, resectable stage IIeIIIb NSCLC
    Cascone, T.
    Awad, M. M.
    Spicer, J. D.
    He, J.
    Lu, S.
    Sepesi, B.
    Tanaka, F.
    Taube, J. M.
    Cornelissen, R.
    Havel, L.
    Kuzdzal, J.
    Petruzelka, L. B.
    Wu, L.
    Pujol, J. L.
    Ito, H.
    Erdmann, C. Coronado
    Sathyanarayana, P.
    Meadows-Shropshire, S.
    Pulla, M. Provencio
    ANNALS OF ONCOLOGY, 2023, 34 : S1295 - S1295
  • [27] Phase III study of perioperative pembrolizumab (pembro) plus neoadjuvant chemotherapy (chemo) versus placebo plus neoadjuvant chemo in cisplatin-eligible patients (pts) with muscle-invasive bladder cancer (MIBC): KEYNOTE-866
    Siefker-Radtke, Arlene O.
    Steinberg, Gary D.
    Bedke, Jens
    Nishiyama, Hiroyuki
    Fang, Xiao
    Kataria, Ritesh
    Moreno, Blanca Homet
    Hoimes, Christopher J.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [28] KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab (pembro) plus chemotherapy (chemo) vs placebo (PBO) plus chemo for previously untreated, locally recurrent, inoperable or metastatic triple-negative breast cancer (mTNBC).
    Cortes, Javier
    Guo, Zifang
    Karantza, Vassiliki
    Aktan, Gursel
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (05)
  • [29] KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab (pembro) plus chemotherapy (chemo) vs placebo (PBO) plus chemo for previously untreated, locally recurrent, inoperable or metastatic triple-negative breast cancer (mTNBC)
    Cortes Castan, J.
    Guo, Z.
    Karantza, V.
    Aktan, G.
    ANNALS OF ONCOLOGY, 2017, 28
  • [30] Phase III KEYNOTE-355 study of pembrolizumab (pembro) vs placebo (pbo) plus chemotherapy (chemo) for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC): Results for patients (Pts) enrolled in Asia
    Yusof, M. Md
    Cescon, D. W.
    Rugo, H. S.
    Im, S-A.
    Gallardo, C.
    Lipatov, O.
    Barrios, C. H.
    Holgado, E.
    Iwata, H.
    Masuda, N.
    Gokmen, E.
    Loi, S.
    Guo, Z.
    Jensen, E.
    Aktan, G.
    Karantza, V.
    Schmid, P.
    Cortes, J.
    ANNALS OF ONCOLOGY, 2020, 31 : S1257 - S1257
12345